Cargando…
Testing the Efficacy of a Multi-Component DNA-Prime/DNA-Boost Vaccine against Trypanosoma cruzi Infection in Dogs
BACKGROUND: Trypanosoma cruzi, the etiologic agent of Chagas Disease, is a major vector borne health problem in Latin America and an emerging infectious disease in the United States. METHODS: We tested the efficacy of a multi-component DNA-prime/DNA-boost vaccine (TcVac1) against experimental T. cru...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098890/ https://www.ncbi.nlm.nih.gov/pubmed/21625470 http://dx.doi.org/10.1371/journal.pntd.0001050 |
_version_ | 1782204014719401984 |
---|---|
author | Aparicio-Burgos, José E. Ochoa-García, Laucel Zepeda-Escobar, José Antonio Gupta, Shivali Dhiman, Monisha Martínez, José Simón de Oca-Jiménez, Roberto Montes Arreola, Margarita Val Barbabosa-Pliego, Alberto Vázquez-Chagoyán, Juan C. Garg, Nisha Jain |
author_facet | Aparicio-Burgos, José E. Ochoa-García, Laucel Zepeda-Escobar, José Antonio Gupta, Shivali Dhiman, Monisha Martínez, José Simón de Oca-Jiménez, Roberto Montes Arreola, Margarita Val Barbabosa-Pliego, Alberto Vázquez-Chagoyán, Juan C. Garg, Nisha Jain |
author_sort | Aparicio-Burgos, José E. |
collection | PubMed |
description | BACKGROUND: Trypanosoma cruzi, the etiologic agent of Chagas Disease, is a major vector borne health problem in Latin America and an emerging infectious disease in the United States. METHODS: We tested the efficacy of a multi-component DNA-prime/DNA-boost vaccine (TcVac1) against experimental T. cruzi infection in a canine model. Dogs were immunized with antigen-encoding plasmids and cytokine adjuvants, and two weeks after the last immunization, challenged with T. cruzi trypomastigotes. We measured antibody responses by ELISA and haemagglutination assay, parasitemia and infectivity to triatomines by xenodiagnosis, and performed electrocardiography and histology to assess myocardial damage and tissue pathology. RESULTS: Vaccination with TcVac1 elicited parasite-and antigen-specific IgM and IgG (IgG2>IgG1) responses. Upon challenge infection, TcVac1-vaccinated dogs, as compared to non-vaccinated controls dogs, responded to T. cruzi with a rapid expansion of antibody response, moderately enhanced CD8(+) T cell proliferation and IFN-γ production, and suppression of phagocytes’ activity evidenced by decreased myeloperoxidase and nitrite levels. Subsequently, vaccinated dogs controlled the acute parasitemia by day 37 pi (44 dpi in non-vaccinated dogs), and exhibited a moderate decline in infectivity to triatomines. TcVac1-immunized dogs did not control the myocardial parasite burden and electrocardiographic and histopatholgic cardiac alterations that are the hallmarks of acute Chagas disease. During the chronic stage, TcVac1-vaccinated dogs exhibited a moderate decline in cardiac alterations determined by EKG and anatomo-/histo-pathological analysis while chronically-infected/non-vaccinated dogs continued to exhibit severe EKG alterations. CONCLUSIONS: Overall, these results demonstrated that TcVac1 provided a partial resistance to T. cruzi infection and Chagas disease, and provide an impetus to improve the vaccination strategy against Chagas disease. |
format | Text |
id | pubmed-3098890 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-30988902011-05-27 Testing the Efficacy of a Multi-Component DNA-Prime/DNA-Boost Vaccine against Trypanosoma cruzi Infection in Dogs Aparicio-Burgos, José E. Ochoa-García, Laucel Zepeda-Escobar, José Antonio Gupta, Shivali Dhiman, Monisha Martínez, José Simón de Oca-Jiménez, Roberto Montes Arreola, Margarita Val Barbabosa-Pliego, Alberto Vázquez-Chagoyán, Juan C. Garg, Nisha Jain PLoS Negl Trop Dis Research Article BACKGROUND: Trypanosoma cruzi, the etiologic agent of Chagas Disease, is a major vector borne health problem in Latin America and an emerging infectious disease in the United States. METHODS: We tested the efficacy of a multi-component DNA-prime/DNA-boost vaccine (TcVac1) against experimental T. cruzi infection in a canine model. Dogs were immunized with antigen-encoding plasmids and cytokine adjuvants, and two weeks after the last immunization, challenged with T. cruzi trypomastigotes. We measured antibody responses by ELISA and haemagglutination assay, parasitemia and infectivity to triatomines by xenodiagnosis, and performed electrocardiography and histology to assess myocardial damage and tissue pathology. RESULTS: Vaccination with TcVac1 elicited parasite-and antigen-specific IgM and IgG (IgG2>IgG1) responses. Upon challenge infection, TcVac1-vaccinated dogs, as compared to non-vaccinated controls dogs, responded to T. cruzi with a rapid expansion of antibody response, moderately enhanced CD8(+) T cell proliferation and IFN-γ production, and suppression of phagocytes’ activity evidenced by decreased myeloperoxidase and nitrite levels. Subsequently, vaccinated dogs controlled the acute parasitemia by day 37 pi (44 dpi in non-vaccinated dogs), and exhibited a moderate decline in infectivity to triatomines. TcVac1-immunized dogs did not control the myocardial parasite burden and electrocardiographic and histopatholgic cardiac alterations that are the hallmarks of acute Chagas disease. During the chronic stage, TcVac1-vaccinated dogs exhibited a moderate decline in cardiac alterations determined by EKG and anatomo-/histo-pathological analysis while chronically-infected/non-vaccinated dogs continued to exhibit severe EKG alterations. CONCLUSIONS: Overall, these results demonstrated that TcVac1 provided a partial resistance to T. cruzi infection and Chagas disease, and provide an impetus to improve the vaccination strategy against Chagas disease. Public Library of Science 2011-05-17 /pmc/articles/PMC3098890/ /pubmed/21625470 http://dx.doi.org/10.1371/journal.pntd.0001050 Text en Aparicio-Burgos et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Aparicio-Burgos, José E. Ochoa-García, Laucel Zepeda-Escobar, José Antonio Gupta, Shivali Dhiman, Monisha Martínez, José Simón de Oca-Jiménez, Roberto Montes Arreola, Margarita Val Barbabosa-Pliego, Alberto Vázquez-Chagoyán, Juan C. Garg, Nisha Jain Testing the Efficacy of a Multi-Component DNA-Prime/DNA-Boost Vaccine against Trypanosoma cruzi Infection in Dogs |
title | Testing the Efficacy of a Multi-Component DNA-Prime/DNA-Boost Vaccine
against Trypanosoma cruzi Infection in Dogs |
title_full | Testing the Efficacy of a Multi-Component DNA-Prime/DNA-Boost Vaccine
against Trypanosoma cruzi Infection in Dogs |
title_fullStr | Testing the Efficacy of a Multi-Component DNA-Prime/DNA-Boost Vaccine
against Trypanosoma cruzi Infection in Dogs |
title_full_unstemmed | Testing the Efficacy of a Multi-Component DNA-Prime/DNA-Boost Vaccine
against Trypanosoma cruzi Infection in Dogs |
title_short | Testing the Efficacy of a Multi-Component DNA-Prime/DNA-Boost Vaccine
against Trypanosoma cruzi Infection in Dogs |
title_sort | testing the efficacy of a multi-component dna-prime/dna-boost vaccine
against trypanosoma cruzi infection in dogs |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098890/ https://www.ncbi.nlm.nih.gov/pubmed/21625470 http://dx.doi.org/10.1371/journal.pntd.0001050 |
work_keys_str_mv | AT aparicioburgosjosee testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs AT ochoagarcialaucel testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs AT zepedaescobarjoseantonio testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs AT guptashivali testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs AT dhimanmonisha testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs AT martinezjosesimon testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs AT deocajimenezrobertomontes testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs AT arreolamargaritaval testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs AT barbabosapliegoalberto testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs AT vazquezchagoyanjuanc testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs AT gargnishajain testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs |